Medicinova, Inc. · NASDAQ:MNOV
Medicinova — Investor Presentation (January 2011)
19 slides from Medicinova's investor presentation, Jan 7, 2011
Slide 1: Accelerating the global development and commercialization of innovative pharmaceuticals
Exhibit 99.1 Accelerating the global development and commercialization of innovative pharmaceuticals © MediciNova, Inc. 2011
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding M
Slide 3: Corporate Overview: MediciNova, Inc.
Corporate Overview: MediciNova, Inc. MediciNova Overview: • Founded in September 2000 • Headquartered in San Diego, CA • Additional office in Tokyo, Japan • Dual-listing on NasdaqGM as MNOVand Osaka Securities Exchange as 4875 • $65.5 million Market Cap (NasdaqGM) as of 1/05/2011 Development Company
Slide 4: MN-221 for Exacerbations of Acute Asthma and COPD
MN-221 for Exacerbations of Acute Asthma and COPD Definition: Hospitalization Rates Amongst • Long-lasting and severe episodes that are not Asthma and COPD Patients* responsive to initial bronchodilator or corticosteroid therapies ~1.9 million Market Opportunity*: • ~500,000 annual hospitalizations
Slide 5: Acute Asthma Treatment Flow in Emergency Departments in the U.S.
Acute Asthma Treatment Flow in Emergency Departments in the U.S. Annual number of Continue therapy until patients with acute patient is discharged *Patients who could Positive potentially benefit from exacerbations of asthma Response 965,000 addition of MN-221 ~51% Patient improves 1,900,000 and is
Slide 6: Limitations of Current Therapies
Limitations of Current Therapies What are the limitations of current therapies for acute exacerbations of asthma? Limitations of Inhaled Therapies: • Bronchoconstriction: inflammation andbronchoconstriction resultininsufficient air flowtogetgooddrugdeposition inthelungs • MucusPlugFormation:mucussec
Slide 7: MN-221: A New Approach to Treating Exacerbations of Acute Asthma & COPD
MN-221: A New Approach to Treating Exacerbations of Acute Asthma & COPD MN-221:A novel,highlyselectiveß 2- adrenergic receptoragonist Three potential advantages over current therapy: 1. Improved Efficacy • Route of Administration (IV v. Inhalation) 2. Improved Safety • Higher selectivity for 2 recep
Slide 8: MN-221: Target Product Profile
MN-221: Target Product Profile MN-221 Indication: Treatment of bronchospasms in patients with acute exacerbations of asthma or COPD. It is administered adjunctive to standard of care by intravenous infusion. • A well-tolerated, ß 2-agonistwhichisonlya partialagonistat ß 1. potent,selective • A bronc
Slide 9: MN-221 Clinical Trials
MN-221 Clinical Trials Completed Ongoing Study CL-004 CL-005 CL-006 CL-010 CL-007 Moderate-to- Acute Moderate-to- Acute Mild-to-moderate Indication Severe Exacerbations Severe Exacerbations Asthmatics Asthmatics of Asthma COPD patients of Asthma FEV1 75% FEV1 80% FEV1 FEV1 60% FEV1 55% FEV1 50% (Ent
Slide 10: MN-221-CL-006 Mean Change in FEV1 and Differences in Hospitalization Rate
MN-221-CL-006 Mean Change in FEV 1 and Differences in Hospitalization Rate Mean change in FEV1 from baseline was 5.3% MN-221 reduced the hospitalization rate by 45% higher in the MN-221 dose groups versus the placebo group © MediciNova, Inc. 2011 10
Slide 11: MN-221-CL-007: Study Design
MN-221-CL-007: Study Design • Randomized, placebo-controlled, double-blind, multi-center Phase II clinical trial • Upto200patientswithsevere,acuteexacerbations ofasthma(FEV1 = 50%predicted) at multiple Emergency Department sites in the United States • Dose Groups (up to 100 patients/group): • 1,200
Slide 12: Ibudilast for the Treatment of MS, Neuropathic Pain, & Drug Addiction
Ibudilast for the Treatment of MS, Neuropathic Pain, & Drug Addiction Ibudilast (MN-166/AV411) • Oral administration • Safe and well-tolerated (approved in Japan/Korea with over 3.2 million exposures) patient • Mechanism(s) of Action primarily Inhibition of Microphage Migration Inhibitor Factor (MIF
Slide 13: Ibudilast (MN-166/AV411): Status for Each Indication
Ibudilast (MN-166/AV411): Status for Each Indication Status for Chronic Pain: • MN-166/AV411 is enabled to go directly to Phase 2b clinical development • MN-166/AV411 mechanism ofactionisnovelandthuscomplimentarytocurrentpaintreatments, and has both stand-alone and adjunctive utilities • Majority of
Slide 14: Ibudilast Neuropathic Pain Market Opportunity
Ibudilast Neuropathic Pain Market Opportunity Total Rxsin 2009 Drug Company • Prevalence is approximately 4.2 (US) million neuropathic pain patients in Lyrica® Pfizer 9.1 Million the U.S. and million 40 worldwide ® Cymbalta Eli Lilly 14.7 Million • MN-166 has a different mechanism of action than cur
Slide 15: Patent/Commercial Overview
Patent/Commercial Overview Method of Use Composition of Matter nd MIF Inh. Progressive 2 Generation MS N. Pain Addiction AV1013 screen MS Analogs Exp. 2018 Exp. 2025 Exp. 2027 Exp. 2027 AV1013 Enantiomer Ibudilast + Acute & Sub- Immunomodulator chronic Pain for MS Issued or Key: Pending allowed © Me
Slide 16: Most Likely Scenario for Ibudilast's Development
Most Likely Scenario for Ibudilast’s Development Collaboration Structure with Pharma Partner: 1. Shared Risk 2. All indications; Ibudilast + Analogues 3. Option Agreement around Phase 2b Diabetic Peripheral Neuropathic Painand/orProgressive MStrialwithExclusive License, Development Milestones, Royal
Slide 17: Commercially-Attractive Diversified Portfolio
Commercially-Attractive Diversified Portfolio Pain/Addiction MS COPD Asthma © MediciNova, Inc. 2011 17
Slide 18: Management Team with Global Experience
Management Team with Global Experience Years Leadership Background Experience Yuichi Iwaki, MD, PhD 35 Professor at USC, formerly Professor at University CEO & President of Pittsburgh; Advisor to JAFCO, Tanabe Shintaro Asako, CPA 13 KPMG USA (Audit), Arthur Andersen USA Chief Financial Officer Kirk
Slide 19: Investment Highlights
Investment Highlights Upcoming Near-Term Business Milestones: 1. Secure a global partnership for Ibudilast (MN-166/AV411) 2. Secure a strategic partnership for MN-221 Upcoming Clinical Milestones: 1. MN-221-CL-007 Phase II Study for Acute Exacerbations of Asthma • Anticipated completion in 2H, 2011*